BioXcel Therapeutics Inc BTAI:NASDAQ

Last Price$15.64NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/12/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$15.50 (1)
Ask (Size)$15.64 (1)
Day Low / HighN/A - N/A
Volume307.4 K
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

BioXcel Therapeutics Inc ( NASDAQ )

Price: $15.64
Change: +0.47 (3.10%)
Volume: 307.4 K
4:00PM ET 8/12/2022
 
 

Aldeyra Therapeutics Inc ( NASDAQ )

Price: $7.47
Change: +0.48 (6.87%)
Volume: 629.4 K
4:00PM ET 8/12/2022
 
 

ADMA Biologics Inc ( NASDAQ )

Price: $2.37
Change: +0.14 (6.28%)
Volume: 4.6 M
4:00PM ET 8/12/2022
 
 

MiMedx Group Inc ( NASDAQ )

Price: $4.14
Change: +0.14 (3.50%)
Volume: 478.5 K
4:00PM ET 8/12/2022
 
 

Radius Health Inc ( NASDAQ )

Price: $10.08
Change: -0.02 (0.20%)
Volume: 6.5 M
4:00PM ET 8/12/2022
 

Read more news Recent News

BioXcel Therapeutics Reports Wider Q2 Net Loss; Shares Fall
10:20AM ET 8/09/2022 MT Newswires

BioXcel Therapeutics (BTAI) reported a Q2 net loss Tuesday of $1.35 per diluted share, widening from a loss of $1.11 a year earlier. Analysts polled by...

BioXcel Therapeutics Says Columbia University Gets NIH Grant to Test BXCL501 to Treat Opioid Withdrawal
10:10AM ET 8/01/2022 MT Newswires

BioXcel Therapeutics (BTAI) said Monday the National Institute on Drug Abuse, which is part of the National Institutes of Health, has awarded Columbia...

--Mizuho Securities Initiates BioXcel Therapeutics at Buy with $19 Price Target
10:27AM ET 7/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Mizuho Initiates BioXcel Therapeutics With Buy Rating, $19 Price Target, Transitioning To 'Revenue-Generating' Story
4:10PM ET 7/06/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionBioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. The firm offers IGALMI, a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. It also develops BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of prostate cancer and solid tumors that are refractory to checkpoint inhibitors. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. View company web site for more details
Address555 Long Wharf Drive
New Haven, Connecticut 06511
Phone+1.475.238.6837
Number of Employees18
Recent SEC Filing08/11/202210-Q
President, Chief Executive Officer & DirectorVimal D. Mehta
Chief Financial Officer & Vice PresidentRichard I. Steinhart
Chief Scientific Officer & Senior Vice PresidentFrank D. Yocca
Chief Medical Officer & Senior Vice PresidentVincent J. O'Neill

Company Highlights

Price Open$15.29
Previous Close$15.17
52 Week Range$8.80 - 36.49
Market Capitalization$437.7 M
Shares Outstanding28.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement11/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.10
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-48.25%

Analyst Ratings as of 07/05/2022

Buy
8
Overweight
0
Hold
0
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset